Which biotechs are most likely to be acquired near-term? We asked Seeking Alpha analysts Edmund Ingham and Terry Chrisomalis for their thoughts on the topic. Read more here.

GSK -4178116 (GSK4178116A) is under development for the prevention of varicella (chickenpox) caused by the new strain (US) of varicella-zoster virus (VZV). It is administered through subcutaneous ...

Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

On Friday, GSK plc (GSK) stock saw a decline, ending the day at $33.47 which represents a decrease of $-0.48 or -1.41% from the prior close of $33.95. The stock opened at $33.98 and touched a low of ...

Central Pacific Bank Trust Division lowered its stake in GSK plc (NYSE:GSK – Free Report) by 1.3% in the fourth quarter, ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Taking precautions to protect yourself from the quartet of infectious diseases can lessen your odds of bringing an illness ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

GSK PLC GSK shares dropped 1.58% to £13.40 Friday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.44% to 8,223.98. Supported by ...

SAN ANTONIO — Austin-based investment firm Evergen Equity has acquired a 309,347-square-foot distribution center in San Antonio. The property at 2 Winnco Drive is located on a 22-acre site at the ...